beyond neda end-organ damage in ms
DESCRIPTION
My talk on NEDA and end-organ damage in Halifax on Wednesday night.TRANSCRIPT
![Page 1: Beyond NEDA end-organ damage in MS](https://reader033.vdocument.in/reader033/viewer/2022060202/559c14091a28abac098b4655/html5/thumbnails/1.jpg)
Beyond NEDA: preventing end-organ damage in MS
Gavin Giovannoni
Blizard Institute, Barts and The London School of Medicine
December 2014
![Page 2: Beyond NEDA end-organ damage in MS](https://reader033.vdocument.in/reader033/viewer/2022060202/559c14091a28abac098b4655/html5/thumbnails/2.jpg)
Disclosures
Over the last 15 years Professor Giovannoni has received personal compensation for participating on Advisory Boards in relation to clinical trial design, trial steering committees and data and safety monitoring committees from: Abbvie, Bayer-Schering Healthcare, Biogen-Idec, Canbex, Eisai, Elan, Fiveprime, Genzyme, Genentech, GSK, GW Pharma, Ironwood, Merck, Merck-Serono, Novartis, Pfizer, Roche, Sanofi-Aventis, Synthon BV, Teva, UCB Pharma and Vertex Pharmaceuticals.
Professor Giovannoni would like to acknowledge and thank Abbvie, Biogen-Idec, Genzyme and Novartis for making available data slides for this presentation. He would also like to thank numerous colleagues for providing him with data and/or slides for this, and other, presentations.
Professor Giovannoni’s tour to Canada has been kindly sponsored by Biogen-Idec, therefore please interpret anything he says about Biogen-Idec’s products in this context.
This presentation has been designed and prepared by Professor Giovannoni with no input from any other parties.
![Page 3: Beyond NEDA end-organ damage in MS](https://reader033.vdocument.in/reader033/viewer/2022060202/559c14091a28abac098b4655/html5/thumbnails/3.jpg)
Who thinks multiple sclerosis should be redefined as a dementia?
![Page 4: Beyond NEDA end-organ damage in MS](https://reader033.vdocument.in/reader033/viewer/2022060202/559c14091a28abac098b4655/html5/thumbnails/4.jpg)
Definition of dementia
Dementia is a loss of mental ability severe enough to interfere with normal activities of daily living, lasting more than six months, not present since birth, and not associated with a loss or alteration of consciousness.
• Normal activities of daily living
• Physical
• Mental
• Social
• Occupational
• Lasting more than six months
• Not present since birth
• Not associated with a loss or alteration of consciousness
![Page 5: Beyond NEDA end-organ damage in MS](https://reader033.vdocument.in/reader033/viewer/2022060202/559c14091a28abac098b4655/html5/thumbnails/5.jpg)
Consequences of increasing EDSS scores: loss of employment1
0
10
20
30
40
50
60
70
80
90
Work Capacity by Disability Level
0.0/1.0 2.0 3.0 4.0 5.0 6.0 6.5 7.0 8.0/9.0
EDSS Score
Pro
po
rtio
n o
f P
ati
en
ts ≤
65
Ye
ars
Old
Wo
rkin
g (
%)
The proportion of patients employed or on long-term sick leave is calculated as a percentage of patients aged 65 or younger.
1. Kobelt G et al. J Neurol Neurosurg Psychiatry. 2006;77:918-926;
2. Pfleger CC et al. Mult Scler. 2010;16:121-126.
Spain
Sweden
Switzerland
United Kingdom
Netherlands
Italy
Germany
Belgium
Austria
~10 yrs2
![Page 6: Beyond NEDA end-organ damage in MS](https://reader033.vdocument.in/reader033/viewer/2022060202/559c14091a28abac098b4655/html5/thumbnails/6.jpg)
Impact of MS: cognitive functioning in the CIS stage
Feuillet et al. MSJ 2007
CIS Patients n = 40
57%
7%
-20%
0%
20%
40%
60%
Healthy Controls n = 30
p < 0.0001
Deficits were found mainly in memory, speed of information
processing, attention and executive functioning Patients failing
≥ 2 cognitive tests
![Page 7: Beyond NEDA end-organ damage in MS](https://reader033.vdocument.in/reader033/viewer/2022060202/559c14091a28abac098b4655/html5/thumbnails/7.jpg)
163 patients with “benign” MS
(disease duration >15 years and EDSS <3.5):
45% cognitive impairment
49% fatigue
54% depression
What is benign MS?
![Page 8: Beyond NEDA end-organ damage in MS](https://reader033.vdocument.in/reader033/viewer/2022060202/559c14091a28abac098b4655/html5/thumbnails/8.jpg)
Definition of dementia
Dementia is a loss of mental ability severe enough to interfere with normal activities of daily living, lasting more than six months, not present since birth, and not associated with a loss or alteration of consciousness.
• Normal activities of daily living
• Physical
• Mental
• Social
• Occupational
• Lasting more than six months
• Not present since birth
• Not associated with a loss or alteration of consciousness
“Multiple sclerosis is a preventable dementia.”
![Page 9: Beyond NEDA end-organ damage in MS](https://reader033.vdocument.in/reader033/viewer/2022060202/559c14091a28abac098b4655/html5/thumbnails/9.jpg)
Control Multiple sclerosis
Slide courtesy of Dr Klaus Schmierer
![Page 10: Beyond NEDA end-organ damage in MS](https://reader033.vdocument.in/reader033/viewer/2022060202/559c14091a28abac098b4655/html5/thumbnails/10.jpg)
Brain atrophy occurs across all stages of the disease
De Stefano, et al. Neurology 2010
n= 963 MSers
![Page 11: Beyond NEDA end-organ damage in MS](https://reader033.vdocument.in/reader033/viewer/2022060202/559c14091a28abac098b4655/html5/thumbnails/11.jpg)
Association of MRI metrics and cognitive impairment in radiologically isolated syndromes
Amato et al. Neurology. 2012 Jan 31;78(5):309-14.
![Page 12: Beyond NEDA end-organ damage in MS](https://reader033.vdocument.in/reader033/viewer/2022060202/559c14091a28abac098b4655/html5/thumbnails/12.jpg)
AAN 2013
![Page 13: Beyond NEDA end-organ damage in MS](https://reader033.vdocument.in/reader033/viewer/2022060202/559c14091a28abac098b4655/html5/thumbnails/13.jpg)
AAN 2013
![Page 14: Beyond NEDA end-organ damage in MS](https://reader033.vdocument.in/reader033/viewer/2022060202/559c14091a28abac098b4655/html5/thumbnails/14.jpg)
11,000 to 1
Trapp, et al. NEJM 1998;338:278-85
![Page 15: Beyond NEDA end-organ damage in MS](https://reader033.vdocument.in/reader033/viewer/2022060202/559c14091a28abac098b4655/html5/thumbnails/15.jpg)
Kutzelnigg, et al. Brain 2005
Is MS a gray matter disease?
Female
Age 46y
SPMS for 16y
Mean ~ 13% GML SPMS ~ 0-69% PPMS ~ 0-39%
Mean ~ 24% WML (SP)
Mean ~ 7% WML (PP)
![Page 16: Beyond NEDA end-organ damage in MS](https://reader033.vdocument.in/reader033/viewer/2022060202/559c14091a28abac098b4655/html5/thumbnails/16.jpg)
Relapses
Unreported relapses
Clinical disease progression
Subclinical relapses: focal MRI activity
Focal gray and white matter lesions not detected by MRI
Brain atrophy
Spinal fluid neurofilament levels
MS Iceberg
Clinical activity
Focal MRI activity
Hidden focal and diffuse MRI activity
Microscopic or biochemical pathology
Biomarkers
![Page 17: Beyond NEDA end-organ damage in MS](https://reader033.vdocument.in/reader033/viewer/2022060202/559c14091a28abac098b4655/html5/thumbnails/17.jpg)
Treatment effect on disability predicted by effect on T2-lesion load and brain atrophy
Meta-analysis of treatment effect on EDSS worsening (y) vs effects on MRI lesions
and brain atrophy, individually or combined, in 13 placebo-controlled RRMS trials
(13,500 patients)
Sormani MP et al. Ann Neurol. 2014;75:43-49.
![Page 18: Beyond NEDA end-organ damage in MS](https://reader033.vdocument.in/reader033/viewer/2022060202/559c14091a28abac098b4655/html5/thumbnails/18.jpg)
Pseudoatrophy and the reversal of pseudoatrophy
Baseline Year 1/2 Year 3
![Page 19: Beyond NEDA end-organ damage in MS](https://reader033.vdocument.in/reader033/viewer/2022060202/559c14091a28abac098b4655/html5/thumbnails/19.jpg)
![Page 20: Beyond NEDA end-organ damage in MS](https://reader033.vdocument.in/reader033/viewer/2022060202/559c14091a28abac098b4655/html5/thumbnails/20.jpg)
No evidence of disease activity: NEDA-3
Gd, gadolinium. 1. Havrdova E, et al. Lancet Neurol 2009; 8:254–260; 2. Giovannoni G, et al. Lancet Neurol 2011; 10:329–337.
Treat-2-target
No evidence of disease activity defined as:1,2
× No relapses
× No sustained disability progression
× No MRI activity
× No new or enlarging T2 lesions
× No Gd-enhancing lesions
![Page 21: Beyond NEDA end-organ damage in MS](https://reader033.vdocument.in/reader033/viewer/2022060202/559c14091a28abac098b4655/html5/thumbnails/21.jpg)
• Post-hoc analysis of a pivotal clinical trial of IFN β-1a IM1
• Treatment with IFN β-1a IM resulted in a 55% reduction in brain atrophy vs. placebo during the second year of a clinical trial (N = 140)
• Analysis of the MRI cohort of the European IFN β-1a IM dose comparison study2
• Derived from a double-dose study; all patients on-treatment; modelled from pre-treatment rate
IFN β-1a IM
BPF, brain parenchymal fraction; IFN β, beta-interferon; IM, intramuscular; MRI, magnetic resonance imaging; n.s., not significant. 1. Rudick RA, et al. Neurology 1999; 53:1698−1704; 2. Hardmeier M, et al. Neurology 2005; 64:236−240.
–1.06% per year
–0.33% per year
Treatment initiation
Month
0.795
0.800
0.805
0.810
0.815
0.820
0.825
0.830
–3 0 3 6 9 12 18 24 30 36 21 15 27 33
BP
F
p < 0.01
n.s.
Year 1
Year 2
Year 3
Month 4−12
Baseline− Month 4
p < 0.05
p < 0.01
n.s.
–1.6
–1.4
–1.2
–1.0
–0.8
–0.6
–0.4
0.0
–0.2
Annual MRI group (n = 368)
Frequent MRI subgroup (n = 138)
Re
lati
ve B
PF
chan
ge (
%)
–0.482% (+/ –0.58)
–0.228% (+/ –0.73)
–0.348% (+/ –0.61)
–0.393% (+/ –0.58)
–0.686% (+/-0.79)
–0.377% (+/-0.77)
–0.378% (+/-0.73)
![Page 22: Beyond NEDA end-organ damage in MS](https://reader033.vdocument.in/reader033/viewer/2022060202/559c14091a28abac098b4655/html5/thumbnails/22.jpg)
Teriflunomide
![Page 23: Beyond NEDA end-organ damage in MS](https://reader033.vdocument.in/reader033/viewer/2022060202/559c14091a28abac098b4655/html5/thumbnails/23.jpg)
TEMSO: 2-year, randomized, placebo-controlled Phase III trial of teriflunomide in patients with RMS (N = 1,088)
Change from baseline in white matter volume
Teriflunomide: white matter atrophy
RMS, relapsing MS. Wolinsky JS, et al. Mult Scler 2013; 19:1310−1319.
• Whole brain atrophy: − no significant effect
• Grey matter atrophy:
− no significant effect
Me
an ±
SE
chan
ge
fro
m b
ase
line
(m
l)
Week
Placebo Teriflunomide 7 mg Teriflunomide 14 mg
2.4
0.8
–0.8
–2.4
–4.0
–5.6
0 24 48 72 108
p = 0.0002
p = 0.0609
No. of patients
Placebo 358 329 309 270 256
7 mg 359 339 301 273 262
14 mg 355 328 293 273 260
![Page 24: Beyond NEDA end-organ damage in MS](https://reader033.vdocument.in/reader033/viewer/2022060202/559c14091a28abac098b4655/html5/thumbnails/24.jpg)
Dimethyl fumarate
![Page 25: Beyond NEDA end-organ damage in MS](https://reader033.vdocument.in/reader033/viewer/2022060202/559c14091a28abac098b4655/html5/thumbnails/25.jpg)
Dimethyl fumarate
DEFINE: 2-year, randomized, placebo-controlled study of DMF in patients with RRMS (N = 1,237)1
CONFIRM: 2-year, randomized, placebo-controlled active reference (GA) comparator study of DMF in patients with RRMS (N = 1,430)2
BID, twice daily; DMF, dimethyl fumarate; TID, three times daily. 1. Arnold DL, et al. AAN 2012. Abstract IN3-2.002; 2. Miller D, et al. ENS 2012. O259.
Week 24−Year 2
−30% vs. placebo (p = 0.02)
−17% vs. placebo (p = 0.2478)
• Significant reduction in brain volume loss vs. placebo with DMF BID but not TID
• No significant reduction in brain volume loss vs. placebo with both doses
−6% vs. placebo
(p = 0.831)
−3% vs. placebo
(p = 0.562)
−16% vs. placebo
(p = 0.706)
Week 24−Year 2
Me
dia
n c
han
ge
in w
ho
le b
rain
vo
lum
e (
%)
Me
dia
n c
han
ge
in w
ho
le b
rain
vo
lum
e (
%)
![Page 26: Beyond NEDA end-organ damage in MS](https://reader033.vdocument.in/reader033/viewer/2022060202/559c14091a28abac098b4655/html5/thumbnails/26.jpg)
Natalizumab
![Page 27: Beyond NEDA end-organ damage in MS](https://reader033.vdocument.in/reader033/viewer/2022060202/559c14091a28abac098b4655/html5/thumbnails/27.jpg)
-1.0%
-0.8%
-0.6%
-0.4%
-0.2%
0.0% Years 0-2
-0.82%
-0.80%
P=0.822†
Placebo (N=315) Natalizumab (N=627)
Year 0-1* Year 1-2
-0.40%
-0.56%
-0.43%
-0.24%
P=0.004†
P=0.002†
†Difference between treatments; ‡Change from baseline; Miller DH et al. Neurology 2007;68:1390-1401.
AFFIRM Study: natalizumab and brain atrophy
Mean
(S
E)
perc
en
tag
e c
han
ge i
n B
PF
![Page 28: Beyond NEDA end-organ damage in MS](https://reader033.vdocument.in/reader033/viewer/2022060202/559c14091a28abac098b4655/html5/thumbnails/28.jpg)
Brain atrophy in natalizumab-treated patients: 3-year follow-up
Sastre-Garriga et al. MSJ 2014.
-0.6%
-1.4%
-0.1% -0.5%
-0.7%
-0.2%
![Page 29: Beyond NEDA end-organ damage in MS](https://reader033.vdocument.in/reader033/viewer/2022060202/559c14091a28abac098b4655/html5/thumbnails/29.jpg)
Alemtuzumab
![Page 30: Beyond NEDA end-organ damage in MS](https://reader033.vdocument.in/reader033/viewer/2022060202/559c14091a28abac098b4655/html5/thumbnails/30.jpg)
Reduction in brain atrophy on alemtuzumab
![Page 31: Beyond NEDA end-organ damage in MS](https://reader033.vdocument.in/reader033/viewer/2022060202/559c14091a28abac098b4655/html5/thumbnails/31.jpg)
Fingolimod
![Page 32: Beyond NEDA end-organ damage in MS](https://reader033.vdocument.in/reader033/viewer/2022060202/559c14091a28abac098b4655/html5/thumbnails/32.jpg)
• In all three studies: PBVC assessed for all patients, prospectively, using the SIENA method • Fingolimod significantly reduced brain volume loss over 2 years vs. placebo
• These reductions were observed after 6 months (first post-baseline scan) • Fingolimod significantly reduced brain volume loss over 1 year vs. IFN β-1a IM
Atrophy data from three fingolimod trials
SIENA, Structural Image Evaluation, using Normalisation, of Atrophy. ITT population with evaluable MRI images at baseline and end of core study phase (Month 24). p values are for comparisons over Months 0–6, Months 0–12, Months 0–24. TRANSFORMS: *** p < 0.001 vs. IFN β-1a IM. Wilcoxon rank sum test; FREEDOMS/FREEDOMS II: * p < 0.05; ** p < 0.01; *** p < 0.001 vs. placebo. Rank ANCOVA adjusted for treatment, region and baseline normalized brain volume. 1. Cohen JA, et al. N Engl J Med 2010; 362:402–415; 2. Kappos L, et al. N Engl J Med 2010; 362:387–401; 3. Radue EW, et al. ECTRIMS 2012. P724.
Me
an P
BV
C f
rom
bas
elin
e
TRANSFORMS1
Time (months)
−32%
reduction
0.0
–0.4
–0.6
–1.4
–0.2
–0.8
–1.2
–1.0
0 24 12
*** n = 429
n = 431
0.0
–0.4
–0.6
–1.4
–0.2
–0.8
–1.2
–1.0
0 24 12 6
FREEDOMS2
Time (months)
−35%
reduction
*
**
***
n = 357
n = 331
0.0
–0.4
–0.6
–1.4
–0.2
–0.8
–1.2
–1.0
0 24 12 6
FREEDOMS II3
Time (months)
−33%
reduction
* ***
*** n = 358
n = 355
Placebo Fingolimod 0.5 mg IFN β-1a IM
![Page 33: Beyond NEDA end-organ damage in MS](https://reader033.vdocument.in/reader033/viewer/2022060202/559c14091a28abac098b4655/html5/thumbnails/33.jpg)
• For all annual BVL thresholds, significantly more NEDA-4 patients were in the fingolimod-treated group than in the placebo group
Results: NEDA-4 by Annual BVL Thresholds
aORs were derived from logistic regression of freedom from disease activity on treatment.
Kappos et al. ACTRIMS/ECTRIMS 2014. FC1.5
80% of subjects fail treatment on this criteria
![Page 34: Beyond NEDA end-organ damage in MS](https://reader033.vdocument.in/reader033/viewer/2022060202/559c14091a28abac098b4655/html5/thumbnails/34.jpg)
Case Study
![Page 35: Beyond NEDA end-organ damage in MS](https://reader033.vdocument.in/reader033/viewer/2022060202/559c14091a28abac098b4655/html5/thumbnails/35.jpg)
Residual deficits: • Walking distance >500m
• Unable to run
• Exercise induces intermittent
sensory symptoms in L arm
• Mild urinary frequency
17-yr girl, myelitis
Jun-2000
1st-yr University
L-optic neuritis
Feb-2001
clumsy
left hand
Jan -2002
pins & needles
in legs
Oct-2003
R optic neuritis
Mar-2004
Brainstem
syndrome;
diplopia and
ataxia
Dec 2007
Cervical cord
relapse
weak L arm
with pain
Jan 2008
Bladder
dysfunction
depression,
anxiety and
fatigue
Reduced
mobility
Mild urinary frequency
No depression ,anxiety
or fatigue
Fully mobile
NEDA (no evident disease activity)
Feb-2008 to May-2014
IFN-beta
Feb-2001
Natalizumab
Jan-2008
ED
SS
IFN-beta Natalizumab Jun-2000 May-2014
6.0
3.5 3.5
![Page 36: Beyond NEDA end-organ damage in MS](https://reader033.vdocument.in/reader033/viewer/2022060202/559c14091a28abac098b4655/html5/thumbnails/36.jpg)
MRI – progressive brain atrophy
Dec 2007 Jul 2010 Jul 2013
Is this patient in long-term remission?
![Page 37: Beyond NEDA end-organ damage in MS](https://reader033.vdocument.in/reader033/viewer/2022060202/559c14091a28abac098b4655/html5/thumbnails/37.jpg)
Overview DMTs and brain atrophy
IV, intravenous.
Therapy Administration Reduction in PBVC
IFN β/GA SC IM
IFN β-1a IM: positive effect Year 2
Teriflunomide Oral Not significant
DMF Oral −30% (for BID in DEFINE); not significant for TID Not significant for both doses in CONFIRM
Fingolimod Oral –35% (FREEDOMS); –33% (FREEDOMS II); –32% (TRANSFORMS)
Natalizumab IV Significant in year 2
Alemtuzumab IV –42% (naive vs. IFN); –24% (previously treated vs. IFN)
![Page 38: Beyond NEDA end-organ damage in MS](https://reader033.vdocument.in/reader033/viewer/2022060202/559c14091a28abac098b4655/html5/thumbnails/38.jpg)
No evidence of disease activity: NEDA-4
Gd, gadolinium. 1. Havrdova E, et al. Lancet Neurol 2009; 8:254–260; 2. Giovannoni G, et al. Lancet Neurol 2011; 10:329–337.
Treat-2-target
No evidence of disease activity defined as:1,2
× No relapses
× No sustained disability progression
× No MRI activity
× No new or enlarging T2 lesions
× No Gd-enhancing lesions
Should we be adding a brain atrophy metric to our definition of NEDA?
Normalisation of brain atrophy rates
![Page 39: Beyond NEDA end-organ damage in MS](https://reader033.vdocument.in/reader033/viewer/2022060202/559c14091a28abac098b4655/html5/thumbnails/39.jpg)
Rheumatoid arthritis End-stage joint disease
![Page 40: Beyond NEDA end-organ damage in MS](https://reader033.vdocument.in/reader033/viewer/2022060202/559c14091a28abac098b4655/html5/thumbnails/40.jpg)
Treating beyond symptoms with a view to improving patient outcomes in inflammatory bowel diseases
Sandborn et al. Journal of Crohn's and Colitis 2014(8):927–935
X
![Page 41: Beyond NEDA end-organ damage in MS](https://reader033.vdocument.in/reader033/viewer/2022060202/559c14091a28abac098b4655/html5/thumbnails/41.jpg)
41
Therapeutic hierarchy
Neuro-restoration
Remyelination
Neuroprotection
Anti-inflammatory
Therapeutic pyramid
Anti-ageing
Brain
Health
Initiative
• Smoking
• Exercise
• Diet
• Sleep
• Co-morbidities
• Infections
• Concomitant
medications
![Page 42: Beyond NEDA end-organ damage in MS](https://reader033.vdocument.in/reader033/viewer/2022060202/559c14091a28abac098b4655/html5/thumbnails/42.jpg)
Conclusions
• MS is a bad disease
• MS is as much a gray matter disease as it is a white matter disease
• Brain volume loss or atrophy
• Present from the earliest stages of the disease
• Occurs at a constant rate (>2x normal)
• Predicts long-term disability
• Associated with cognitive impairment
• Should MS be reclassified as a dementia?
• Or at least a preventable dementia?
• Being accepted as a preventable dementia will help drive adoption of early effective treatment and zero tolerance (T2T-NEDA-ZeTo)
• Should we include brain atrophy as part of our treatment target?
• NEDA-4